Ajinomoto Bio-Pharma Services
San Diego, CA · Osaka, JP
Program data pending ClinicalTrials.gov matching
· Last scored 2026-10-29
83.5
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (12)
○ EMA GMP
✓ MHRA GMP (1)
✓ HC GMP (12)
Quick Facts: Ajinomoto Bio-Pharma Services
- Signal Score
- 83.5/100 (as of 2026-10-29)
- Quality Compliance
- 100.0/100
- Headquarters
- San Diego, CA · Osaka, JP
- Modalities
- Oligonucleotide, Biologics, AAV
- Active Programs
- No ClinicalTrials.gov matches confirmed — 6 partnership signals in press (announcements, not verified)
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Ajinomoto Bio-Pharma Services
Acquired Forge Biologics. Expanding into CGT.
Signal Score & Pillar Breakdown
Quality Compliance
100.0
FDA InspectionsNo US records on file
MHRA GMP Certificates1 on record
Most Recent HC OutcomeCompliant · 2023-09-12
HC Attribution12 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer. 6 partnership announcements found in press monitoring.
Programs
— no verified data
Sponsors— no verified data
ModalitiesOligonucleotide, Biologics, AAV
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Partnership Signals (from press monitoring)
Company announcements, not verified evidence.
Financial Stability
75.0
Strong parent backing: Ajinomoto Co. (2802.T)
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Strong parent backing: Ajinomoto Co. (2802.T)
Capacity
63.0
2 manufacturing sites
Sites: San Diego, CA, Osaka, Japan
Source: company profiles (manufacturing sites, modality breadth)
2 manufacturing sites
Press Signals12 articles (not scored)
2 manufacturing sites
Ajinomoto Bio-Pharma Services MHRA GMP Compliance 1 certificates
2014-06
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK GMP 33833 Insp GMP 33833/586518-0001[H] | AJINOMOTO ALTHEA INCORPORATED | 92121-1205 | 2014-06-19 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Nov 21, 2026
Japan-accredited overseas site (PMDA)
No current accreditation on PMDA's list.
Previously accredited (cancelled) · 1
- San Diego, United States · Ajinomoto Althea, Inc. (2 sites) — sterile, biologics, packaging/storage only · cancelled Oct 6, 2025
No longer on PMDA's current list. Shown for history only; not used in search tags.
PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Nov 20, 2026
Company Signals 12 articles
Company announcements, not verified evidence. They do not change any score.
Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand Identity - BioPharma APAC
Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand Identity BioPharma APAC
Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to support ADC development and manufacturing - BioSpectrum India
Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to support ADC development and manufacturing BioSpectrum India
Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to support ADC development and manufacturing - BioSpectrum India
Piramal Pharma Solutions partners with Ajinomoto Bio-Pharma Services to support ADC development and manufacturing BioSpectrum India
Piramal Pharma, Ajinomoto Bio-Pharma collaborate to accelerate ADC development - Indian Pharma Post
Piramal Pharma, Ajinomoto Bio-Pharma collaborate to accelerate ADC development Indian Pharma Post
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing - Yahoo Finance
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing Yahoo Finance
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing - PA Media
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing PA Media
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing - acrofan.com
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing acrofan.com
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing - digitalmore.co
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing digitalmore.co
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing - PR Newswire
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and Manufacturing PR Newswire
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and... - lokmattimes.com
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services Collaborate to Support ADC Development and... lokmattimes.com
Piramal Pharma Solutions und Ajinomoto Bio-Pharma Services arbeiten zusammen, um die Entwicklung und Herstellung von ADCs zu unterstützen - PR Newswire
Piramal Pharma Solutions und Ajinomoto Bio-Pharma Services arbeiten zusammen, um die Entwicklung und Herstellung von ADCs zu unterstützen PR Newswire
Piramal Pharma, Ajinomoto Bio-Pharma collaborate to accelerate ADC development - Indian Pharma Post
Piramal Pharma, Ajinomoto Bio-Pharma collaborate to accelerate ADC development Indian Pharma Post
Frequently Asked Questions About Ajinomoto Bio-Pharma Services
Does Ajinomoto Bio-Pharma Services hold EMA or MHRA GMP certificates?
CDMO Signal tracks 1 MHRA GMP certificate for Ajinomoto Bio-Pharma Services.
What is Ajinomoto Bio-Pharma Services's CDMO Signal Score?
Ajinomoto Bio-Pharma Services has a Signal Score of 84/100, based on quality, operations, financial stability, and capacity data.
Evaluating Ajinomoto Bio-Pharma Services for a manufacturing program?
Use the free AI matchmaker to compare Ajinomoto Bio-Pharma Services against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
Signal Score: 83.1
mRNA, Oligonucleotide, Biologics
Lotte Biologics
Incheon, KR · Syracuse, NY
Signal Score: 81.6
Biologics, AAV
BioReliance (Merck)
Glasgow, UK · Rockville, MD
Signal Score: 80.3
AAV, Lentiviral, Biologics
Curia (RNA/Advanced)
Albany, NY · Albuquerque, NM
Signal Score: 79.5
mRNA, Oligonucleotide, Biologics
Compare Ajinomoto Bio-Pharma Services with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.